# Chong‐Rui Xu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/chong-rui-xu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,553 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 37 |
| i10-index | 72 |
| Last Known Institution | Guangdong Academy of Medical Sciences |
| OpenAlex ID | https://openalex.org/A5009003205 |
| ORCID iD | 0000-0002-3474-2809 |
| Works | 280 |

## Researcher papers

- [Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial](https://scholariq.org/papers/afatinib-versus-cisplatin-plus-gemcitabine-for-first-line-treatment-of-asian/)
- [EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer](https://scholariq.org/papers/egfr-mutation-correlates-with-uninflamed-phenotype-and-weak-immunogenicity/)
- [Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy](https://scholariq.org/papers/unique-genetic-profiles-from-cerebrospinal-fluid-cell-free-dna-in-leptomeningeal/)
- [HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers](https://scholariq.org/papers/her2-mediated-internalization-of-cytotoxic-agents-in-i-erbb2-i-amplified-or/)
- [Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma](https://scholariq.org/papers/specific-tp53-subtype-as-biomarker-for-immune-checkpoint-inhibitors-in-lung/)
- [Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/relative-abundance-of-i-egfr-i-mutations-predicts-benefit-from-gefitinib/)
- [Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study](https://scholariq.org/papers/bevacizumab-plus-erlotinib-in-chinese-patients-with-untreated-egfr-mutated/)
- [Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer](https://scholariq.org/papers/overall-survival-with-circulating-tumor-dna-guided-therapy-in-advanced-non-small/)
- [Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China](https://scholariq.org/papers/epidermal-growth-factor-receptor-mutations-and-their-correlation-with-gefitinib/)
- [A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer](https://scholariq.org/papers/a-comprehensive-review-of-uncommon-egfr-mutations-in-patients-with-non-small/)
- [A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival](https://scholariq.org/papers/a-potential-treatment-option-for-transformed-small-cell-lung-cancer-on-pd-l1/)
- [MA12.08 Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/ma12-08-chemotherapy-plus-egfr-tkis-or-bevacizumab-versus-chemotherapy-alone-in/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Guangdong Academy of Medical Sciences](https://scholariq.org/institutions/guangdong-academy-of-medical-sciences/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.